Extended endocrine therapy with an aromatase inhibitor did not improve disease-free survival in patients with hormone receptor–positive breast cancer enrolled in three studies presented at the 2016 San Antonio Breast Cancer Symposium.
The results stand in contrast to the phase III National Cancer...
Clearly, decisions about extended treatment will now be individualized.— Michael Gnant, MD
Michael Gnant, MD, Professor of Surgery at the Medical University of Vienna in Austria and President of the Austrian Breast & Colorectal Cancer Study Group, was the invited...!-->!-->
With a truly national survivorship infrastructure, as the fear of cancer begins to fade, so too will the burdens faced by survivors.— (Left) Janet Snapp, MSN, RN, FPCN, and Dori Klemanski, DNP, CNP, RN
Although a cure for cancer remains elusive, there are many...!-->!-->!-->!-->
The issue is not what we call a Gleason 6, but whether it has the potential to progress. Researchers currently are looking at genetic signatures that can differentiate a nonthreatening Gleason 6 from one that will progress to Gleason 7 or higher and possibly metastasize.!-->!-->— ...
Children with acute lymphoblastic leukemia (ALL) considered at standard risk for relapse should continue to receive standard-intensity regimens, according to findings from the international randomized AIEOP-BFM ALL 2000 trial.1
Our study underlines the importance of...!-->!-->
Randomized trials testing reductions in treatment intensity are challenging to conduct but are the best way to answer the critical question of who can be cured with less therapy.— Stephen P. Hunger, MD
Stephen P. Hunger, MD, Chief of the Division of Pediatric Oncology...!-->!-->
Tyrosine kinase inhibitors, such as imatinib, nilotinib (Tasigna), and dasatinib (Sprycel), have revolutionized the treatment of chronic myeloid leukemia (CML). A substantial percentage of patients achieve deep and meaningful remissions on these agents. More recently, partly driven by patients’ and ...
If I see more data reassuring me that the depth of remission is the same when relapsed patients are re-started on therapy, then I will re-think the strategy of stopping tyrosine kinase inhibitors.— Mikkael Sekeres, MD
In his practice, Mikkael Sekeres, MD, of the...!-->!-->
The importance of achieving complete response after intensive therapy in older adults with acute myeloid leukemia (AML) was confirmed in a follow-up analysis of the E2906 North American Intergroup trial.1 Patients in complete response had superior survival in this landmark analysis. This finding...
Complete remission remains a robust criterion in AML—better than other response criteria—and there is a growing interest in minimal residual disease to allow us to tease out the depth of remission.— Amir T. Fathi, MD
“In the past few years, there has been increased...!-->!-->
Eight individuals were honored at the 2016 MPN Heroes celebration held on the eve of the American Society of Hematology’s (ASH) Annual Meeting & Exposition in San Diego. The MPN Hero award is given by Cure magazine in recognition of an individual’s commitment to helping patients with...
Lawrence N. Shulman, MD, FACP
Lawrence N. Shulman, MD, FACP, Professor of Medicine in the Perelman School of Medicine and Deputy Director for Clinical Services of the Abramson Cancer Center at the University of Pennsylvania, has been named the new Chair of the Commission on Cancer of the...!-->!-->
Nancy Thomas, MD, PhD
University of North Carolina (UNC) Lineberger Comprehensive Cancer Center member Nancy Thomas, MD, PhD, has been named Chair of the Department of Dermatology, effective January 1. She assumes the role from Luis Diaz, MD, who is stepping down from the position after...!-->!-->
Additional interventions following upfront autologous stem cell transplant in multiple myeloma did not further improve progression-free or overall survival over transplant alone in a multicenter study presented as a late-breaking abstract at the 2016 American Society of Hematology (ASH) Annual...
We see that transplant and maintenance alone benefits a lot of patients. It is also probably the most cost-effective treatment for myeloma at this time.— Sergio A. Giralt, MD
Sergio A. Giralt, MD, Chief of the Adult Bone Marrow Transplant Service at Memorial Sloan...!-->!-->
Induction and maintenance therapies with obinutuzumab (Gazyva) were superior to rituximab (Rituxan) induction and maintenance in patients with untreated follicular lymphoma, according to results of the phase III GALLIUM study presented at the Plenary Session during the 58th American Society of...
Obinutuzumab may get a front-line indication for follicular lymphoma based on this study.— Brad S. Kahl, MD
Speaking about the GALLIUM study in the ASH News Daily, Brad S. Kahl, MD, of Washington University School of Medicine, St. Louis, commented, “It is a potentially...!-->!-->
Long-awaited results of the Cancer and Leukemia Group B (CALGB)/Alliance 50303 trial were a disappointment to many hematologists/oncologists at the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition. The study failed to show that dose-adjusted EPOCH-R (etoposide,...
Lawrence Kaplan, MD
“This study is important because R-CHOP [rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone] has been the standard of care for many years. CHOP, the chemotherapy backbone, has withstood challenges from more aggressive regimens in the past. The...!-->!-->
Thirty of 32 complete remissions were achieved with only one round of chemotherapy. This means 4 weeks in the hospital rather than 6 to 8 weeks, and this is important to patients.— Harry P. Erba, MD, PhD
The investigational CD33-directed antibody-drug conjugate...!-->!-->
In these initial studies, vadastuximab appears to be at least as good as, and maybe better than, gemtuzumab ozogamicin. It is certainly a route for bringing an anti-CD33 monoclonal antibody back to market in AML.— Mikkael A. Sekeres, MD, MS
Mikkael A. Sekeres, MD, MS,...!-->!-->
Induction therapy with the experimental chemotherapy called CPX-351—a liposomal formulation of cytarabine and daunorubicin—outperformed standard “7+3” cytarabine plus daunorubicin by extending survival in older high-risk patients with acute myeloid leukemia (AML) who subsequently underwent...
One of the issues in high-risk AML in older patients is that remissions can be achieved, but they are not durable. The concept is reasonable that CPX-351 may provide not only a bridge to transplant, but increase the likelihood of transplant success....!-->!-->— Armand Keating, MD
Gilberto de Lima Lopes, Jr, MD, MBA, FAMS
ASCO announced that Gilberto de Lima Lopes, Jr, MD, MBA, FAMS, will become Editor-in-Chief of the Society’s Journal of Global Oncology (JGO) in early 2017. Dr. Lopes will direct the editorial scope of JGO, an online-only, open-access journal...!-->!-->
Clifford Hudis, MD, FACP, FASCO
On Tuesday, December 13, President Obama signed into law the 21st Century Cures Act, landmark legislation designed to improve and accelerate the pace of biomedical research in the United States. ASCO Chief Executive Officer Clifford Hudis, MD, FACP, FASCO,...!-->!-->
The addition of everolimus (Afinitor) to fulvestrant (Faslodex) doubled progression-free survival in postmenopausal women with hormone receptor–positive, HER2-negative metastatic breast cancer resistant to aromatase inhibitor therapy compared with fulvestrant plus placebo, according to the...
Everolimus and fulvestrant is another standard-of-care option, and with the evidence from this trial, I won’t have to fight insurance companies for reimbursement.— Virginia Kaklamani, MD
How can the results of this trial be applied to clinical practice? Press conference ...!-->!-->
Researchers working on whole-exome and transciptome sequencing of endocrine-resistant estrogen receptor–positive metastatic breast cancer have shown that the mutational landscape differs from that of estrogen receptor–positive primary breast cancer, and these differences have the potential to...
Young women who carry the BRCA1 and/or BRCA2 mutation and develop breast cancer seem to have similar survival compared with young women who have BRCA-negative breast cancer. However, women with BRCA-positive triple-negative breast cancer have an 11% survival advantage compared with those with...
The take-home message from the POSH trial is that by using treatment that is still standard of care, [patients with] BRCA-positive breast cancer have outcomes that are not worse than BRCA-negative patients.— Leif Ellisen, MD, PhD
Results of this trial have been...!-->!-->
As neoadjuvant therapy, abemaciclib alone or in combination with anastrozole achieved strong signals of anticancer activity in postmenopausal patients with hormone receptor–positive, HER2-negative breast cancer in the neoMONARCH phase II study.1 Abemaciclib alone or in combination with anastrozole...
Press conference moderator Carlos L. Arteaga, MD, said: “This drug is not necessarily the same as palbociclib [Ibrance] or ribociclib. There are subtle differences among these three [cyclin-dependent kinase (CDK) 4/6] inhibitors. The tissue analysis provides us with an enormous opportunity to...
Correlative science studies, evaluation of residual cancer burden, and long-term outcomes may help define the role of estrogen deprivation in the treatment of HER2-positive early breast cancer.— Mothaffar F. Rimawi, MD
The addition of estrogen deprivation to neoadjuvant ...!-->!-->
Myles Brown, MD
Myles Brown, MD, Director of the Center for Functional Cancer Epigenetics at Dana-Farber Cancer Institute, Boston, suggested the failure of the endocrine therapy to increase the pathologic complete response rates “may be related to the fact that the aromatase inhibitor was...!-->!-->
The pan-phosphoinositide 3-kinase (PI3K) inhibitor buparlisib combined with fulvestrant (Faslodex) prolonged progression-free survival compared with placebo and fulvestrant in postmenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer previously treated with an...
We learned from this study that inhibiting all the PI3K isoenzymes with drugs like buparlisib is associated with undue toxicity. However, this study gives us further impetus to develop PI3K-alpha inhibitors.— Carlos L. Arteaga, MD
Press conference moderator Carlos L....!-->!-->
The SIO conference has become a source for high-quality research as well as a place for everyone from naturopaths, acupuncturists, and nutritionists to nurses and physicians to connect and get a broad perspective of what’s happening in this field.!-->!-->— Lynda Balneaves, PhD,...
The following five abstracts were chosen as the best submitted studies presented at this year’s International Conference of the Society for Integrative Oncology (SIO). They represent a diverse group of integrative therapies and interventions in the care of patients with cancer, including an...
Stuart M. Lichtman, MD
Geriatrics for the Oncologist is guest edited by Stuart M. Lichtman, MD, and developed in collaboration with the International Society of Geriatric Oncology (SIOG). Dr. Lichtman is an Attending Physician at Memorial Sloan Kettering Cancer Center, Commack,...
One of the featured “Big Debates” at the 2016 World Cancer Congress in Paris addressed this question: Are scarce resources best applied to prevention rather than treatment?
Richard Larson, MD
Many experts do not see prevention vs treatment in such stark terms or even as a realistic...!-->!-->
The global biopharmaceutical company AbbVie has announced collaborations with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Johns Hopkins University School of Medicine. These 5-year partnerships to advance cancer research and discovery in oncology will focus on...
Nancy G. Hesse, MSN, RN
Cancer Treatment Centers of America (CTCA), a national network of five cancer hospitals, announced that Nancy G. Hesse, MSN, RN, has been named President and Chief Executive Officer (CEO) of its Eastern Regional Medical Center (Eastern) in Philadelphia. Ms. Hesse...!-->!-->
Richard Gorlick, MD
Richard Gorlick, MD, an expert in pediatric oncology and hematology, has joined The University of Texas MD Anderson Children’s Cancer Hospital as the Division Head and Department Chair of Pediatrics.
A pediatric cancer survivor himself, Dr. Gorlick committed his life’s ...!-->!-->
There has been no better time than the present for women in the field of oncology: Women at all stages of their careers are finding more opportunities and avenues to excel. At the time of the last ASCO workforce survey, women made up 28.4% of the oncologist workforce, and that proportion is rising...
The Conquer Cancer Foundation has an incredible opportunity for you to make an amazing impact!
An anonymous donor is offering a Matching Gift Challenge, which will double the value of every gift we receive by December 31—dollar for dollar—up to $64,000! This amount is enough to fund one of...
The results of every Presidential election offer both challenges and opportunities for ASCO’s advocacy efforts. ASCO’s mission is to help practices and patients with cancer thrive—in every setting and in every community. Through each administration and Congress, the Society works closely with...
ASCO and the Oncology Nursing Society (ONS) have updated their chemotherapy administration safety standards to include pediatric oncology care. The updated standards can be found in the Journal of Oncology Practice.1
In 2009, ASCO and the Oncology Nursing Society published the initial set of...
Help your patients manage the financial impact of a cancer diagnosis with Cancer.Net’s Managing the Cost of Cancer Care booklet. This booklet provides information on key financial categories for cancer care; an easy-to-understand explanation of health insurance coverage; information about...
In the phase III PALOMA-2 trial reported in The New England Journal of Medicine, Richard S. Finn, MD, of the David Geffen School of Medicine at the University of California, Los Angeles, and colleagues found that the addition of palbociclib (Ibrance) to letrozole significantly improved...
Women with hormone receptor–positive metastatic breast cancer are witnessing an unprecedented time of success in the battle against their disease. Just in the past 12 months, a number of prospective, randomized, phase III studies were reported, with positive results indicating the value of...
In a study reported in Nature Genetics, Bishoy M. Faltas, MD, of Weill Cornell Medicine, and colleagues identified factors in the clonal evolution of chemotherapy-resistant urothelial carcinoma.1 As stated by the investigators: “Chemotherapy-resistant urothelial carcinoma has no uniformly curative...
Radical cystectomy with urinary diversion is the standard of care for muscle invasive bladder cancer.1 Meta-analyses of prospective data have shown a 5% overall survival benefit at 5 years for those receiving neoadjuvant systemic chemotherapy prior to cystectomy.2,3 We currently know of two...
On November 17, 2016, the American Society for Radiation Oncology (ASTRO) issued an updated clinical practice statement for accelerated partial-breast irradiation for early-stage breast cancer. The updated guideline reflects recent evidence that greater numbers of patients may benefit from...
W.K. Alfred Yung, MD
W.K. Alfred Yung, MD, has wanted a career in medicine since he was a high-school student and has spent nearly 4 decades fulfilling that dream, specifically in the research and treatment of one of the deadliest cancers, malignant brain tumor, especially glioblastoma...!-->!-->
Jamie H. Von Roenn, MD
Addressing the evolving needs of cancer survivors at various stages of their illness and care, Palliative Care in Oncology is guest edited by Jamie H. Von Roenn, MD. Dr. Von Roenn is ASCO’s Senior Director of Education, Science and Professional...
Ellis J. Neufeld, MD, PhD
Ellis J. Neufeld, MD, PhD, has been appointed Clinical Director, Physician-in-Chief, and Executive Vice President of St. Jude Children’s Research Hospital.
Dr. Neufeld’s appointment will begin in March 2017. In this role, Dr. Neufeld will oversee the...!-->!-->
Monica M. Bertagnolli, MD
Monica M. Bertagnolli, MD, a long-time ASCO member and volunteer, has been elected to serve as the President of ASCO for the term beginning in June 2018. She will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2017. Additionally,...!-->!-->
2017 Oncologic Emergency Medicine Conference
January 12-13 • Houston, Texas
For more information:
2017 Highlights of ASH in North America
The following essay by Jeremy K. Hon, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org.
Amit Kumar, PhD
Joseph M. Naylor
William D. Novelli
Arnold M. Baskies,
Kevin J. Cullen,
Lewis E. Foxhall,
Scarlott K. Mueller,
The American Cancer Society announced the election of ...!-->!-->!-->!-->!-->!-->!-->!-->!-->!-->!-->!-->!-->!-->!-->!-->
Women’s life expectancy is pushing into the 80s, and some people live until they are 100. So there is good reason for new studies to look at older people.— Cindy S. Lee, MD
An analysis of data from nearly 6 million screening mammograms found no evidence for a clear...!-->!-->
In the discussion between patient and doctor, the focus here is patient-centered care. It shouldn’t be about this ‘magic number’ of 75, after which you are no longer allowed to participate in screening.— Cindy S. Lee, MD
A study finding that there is no clear cutoff age to stop breast...
R. Daniel Beauchamp, MD
R. Daniel Beauchamp, MD, Chair of the Section of Surgical Sciences and the John Clinton Foshee Distinguished Professor of Surgery at the Vanderbilt-Ingram Cancer Center, has been selected to receive the 2016 Dr. Rodman E. and Thomas G. Sheen Award from the New...!-->!-->
Even now, 25 years later, although he is no longer my oncologist, we talk twice a year to wish each other a happy birthday, and I cherish those calls.— Shirley Grandahl
Twenty-five years ago, I was a physically fit woman of 45 in training to run a marathon, which had...!-->!-->
In a phase II Canadian Pediatric Brain Tumor Consortium Study reported in the Journal of Clinical Oncology, Lassaletta et al found that vinblastine monotherapy was associated with response or stable disease in most children with chemotherapy-naive low-grade glioma. Vinblastine monotherapy has shown ...
A large population-based observational study by Xabier García-Albéniz, MD, PhD, of the Harvard T.H. Chan School of Public Health, and colleagues evaluating the effectiveness and safety of screening colonoscopy for the prevention of colorectal cancer in people aged 70 to 74 and 75 to 79 has found...
In a phase II trial reported in The Lancet Oncology, Glenwood Goss, MD, of The Ottawa Hospital Cancer Centre, University of Ottawa, and colleagues found that osimertinib produced a high response rate in EGFR tyrosine kinase inhibitor–pretreated EGFR Thr790Met (T790M)–positive advanced non–small...
Maintenance olaparib (Lynparza) appeared to be associated with an overall survival benefit vs placebo in women with platinum-sensitive serous ovarian cancer and BRCA1 and BRCA2 mutations, according to an updated analysis of a phase II trial reported in The Lancet Oncology by Jonathan A. Ledermann,...
Venous thromboembolism is a serious—and sometimes fatal—complication of cancer and chemotherapy treatment. Since breast cancer is one of the most common cancers, it accounts for a large number of cancer-related cases of venous thromboembolism. Routine thromboprophylaxis, however, is not recommended ...